PEPTiPEN RETA

PEPTiPEN RETA supplies Retatrutide (LY-3437943) for in vitro and preclinical research applications. Retatrutide is a triple-receptor peptide agonist studied in research models for its activity at GLP-1, GIP, and glucagon receptors.

Triple-Receptor Activity

Retatrutide has been investigated in published Phase II clinical trials for its receptor activation profile. Research data reported an average of approximately 24% change in body weight parameters over 48 weeks in the trial population. This data is provided for scientific reference only.

• GLP-1, GIP, and Glucagon receptor agonist - research compound
• Studied for appetite signalling pathways in preclinical models
• Investigated for metabolic rate pathways via glucagon receptor activity
• Examined in research settings for glucose and insulin sensitivity markers
• Preclinical research into body composition parameters

Active Compound

Retatrutide (LY-3437943) - sterile, research-grade. 10mg per cartridge. For research use only.

Delivery System

Precision auto-injector research pen with 0.01mg dose increments, stainless steel mechanism, replaceable cartridge. For in vitro and preclinical research use only. Not approved for human or veterinary administration.

Research Use Only Disclaimer: This product is intended solely for in vitro research and preclinical study purposes. It is not approved, licensed, or intended for use in humans or animals. The information provided is derived from published scientific literature and is presented for research context only. It does not constitute medical advice. Consult a qualified healthcare professional before any administration involving biological systems.